TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
To describe the clinical response rate in two groups (Docetaxel plus cisplatin plus 5-FU, versus Cisplatin plus 5-FU) after 3 cycle of neoadjuvant chemotherapy.
Carcinoma, Squamous Cell
DRUG: Docetaxel
Clinical response will be evaluated by modified WHO criteria. Clinical and radiological assessment of all lesions will be performed, After 2 cycle, 3 cycle and after concurrent chemo/radiotherapy.
Pathologic response if clinical response of primary tumor is CR at the end of chemotherapy and end of concurrent chemo/ radiotherapy, biopsy of primary tumor site will be performed to evaluate pathologic response rate.
To describe the clinical response rate in two groups (Docetaxel plus cisplatin plus 5-FU, versus Cisplatin plus 5-FU) after 3 cycle of neoadjuvant chemotherapy.